yingweiwo

Alalevonadifloxacin

Alias: WCK2349 Alalevonadifloxacin WCK-2349 WCK 2349
Cat No.:V6981 Purity: ≥98%
Alalevonadifloxacin is a novel and potent antibacterial drug
Alalevonadifloxacin
Alalevonadifloxacin Chemical Structure CAS No.: 706809-20-3
Product category: New1
This product is for research use only, not for human use. We do not sell to patients.
Size Price
500mg
1g
Other Sizes

Other Forms of Alalevonadifloxacin:

  • Alalevonadifloxacin HCl
  • Alalevonadifloxacin mesylate
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description
Alalevonadifloxacin is a novel and potent antibacterial drug
Alalevonadifloxacin (CAS 706809-20-3), also known as WCK 2349, is a novel l-alanine ester prodrug of the quinolone antibacterial levonadifloxacin. It functions as a dual inhibitor of bacterial DNA gyrase and topoisomerase IV. The compound is potentially useful for treating Gram-positive, Gram-negative, and anaerobic bacterial infections. It has been developed by Wockhardt and has shown ~89% oral bioavailability. Phase II clinical trials are ongoing for MRSA and skin and soft tissue infections.
Biological Activity I Assay Protocols (From Reference)
Targets
Alalevonadifloxacin targets bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication and survival. By inhibiting DNA gyrase, the compound prevents the supercoiling of bacterial DNA necessary for replication and transcription. Inhibition of topoisomerase IV interferes with the decatenation of replicated DNA, preventing chromosome segregation during cell division. This dual targeting results in potent bactericidal activity against a broad spectrum of bacteria, including drug-resistant strains.
ln Vitro
In vitro, Alalevonadifloxacin demonstrates potent antibacterial activity against a broad spectrum of bacteria, including Gram-positive, Gram-negative, and anaerobic pathogens. The compound shows notable potency against methicillin-resistant Staphylococcus aureus (MRSA). As a quinolone antibacterial, it inhibits bacterial DNA gyrase and topoisomerase IV. The prodrug is converted to the active moiety levonadifloxacin, which exerts its antibacterial effects. Its activity has been characterized in various bacterial strains, with efficacy against drug-resistant organisms.
ln Vivo
In vivo, Alalevonadifloxacin is orally active with ~89% oral bioavailability. The prodrug is converted to levonadifloxacin, which distributes to tissues including plasma, epithelial lining fluid, and alveolar macrophages. Phase II clinical trials are ongoing for the treatment of methicillin-resistant Staphylococcus aureus infections and skin and soft tissue infections. Intrapulmonary pharmacokinetic studies have been conducted in healthy adult subjects. The compound shows potential for treating both systemic and respiratory infections.
Enzyme Assay
The in vitro antibacterial susceptibility assay for Alalevonadifloxacin involves testing the compound against various bacterial strains using standard methods such as broth microdilution according to CLSI guidelines. Bacterial inocula are prepared from overnight cultures and adjusted to the appropriate density. Serial dilutions of the compound are prepared in growth medium, and bacterial suspensions are added. Plates are incubated at 37°C for 18-24 hours, and the minimum inhibitory concentration (MIC) is determined. DNA gyrase and topoisomerase IV inhibition is assessed by measuring the compound's ability to inhibit supercoiling and decatenation activities of purified enzymes in vitro.
Cell Assay
For in vitro cellular assays, Alalevonadifloxacin is tested in bacterial cultures to assess its effects on bacterial growth and viability. Bacteria are treated with the compound at various concentrations for defined periods. Bacterial growth is measured by optical density at 600 nm. Viability is assessed by colony counting on agar plates. DNA synthesis inhibition is measured by incorporation of radiolabeled thymidine. The compound's effects on bacterial morphology are assessed by microscopy. Resistance development is studied by serial passage in the presence of sub-inhibitory concentrations. The prodrug's conversion to levonadifloxacin is assessed in cell culture or liver microsome preparations.
Animal Protocol
In vivo animal experiments for Alalevonadifloxacin would typically use mouse models of bacterial infection. Animals are infected with bacterial pathogens and treated with the compound orally or intravenously at various doses and schedules. Survival is monitored as the primary endpoint. Bacterial burden in tissues is measured by colony counting. Pharmacokinetic studies are conducted to determine the compound's bioavailability, distribution, and elimination. Intrapulmonary pharmacokinetics have been studied in healthy human subjects, with levonadifloxacin concentrations measured in plasma, epithelial lining fluid, and alveolar macrophages following oral administration of alalevonadifloxacin.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C22H26FN3O5
Molecular Weight
431.457349300385
Exact Mass
431.185
CAS #
706809-20-3
Related CAS #
396132-82-4 (HCl);706809-20-3;948895-94-1 ( mesylate);
PubChem CID
16734914
Appearance
Typically exists as solid at room temperature
LogP
0.7
tPSA
113
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
9
Rotatable Bond Count
5
Heavy Atom Count
31
Complexity
781
Defined Atom Stereocenter Count
2
SMILES
C[C@H]1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)OC(=O)[C@H](C)N)F)C(=O)O
InChi Key
OUXXDXXQNWKOIF-RYUDHWBXSA-N
InChi Code
InChI=1S/C22H26FN3O5/c1-11-3-4-14-18-15(20(27)16(21(28)29)10-26(11)18)9-17(23)19(14)25-7-5-13(6-8-25)31-22(30)12(2)24/h9-13H,3-8,24H2,1-2H3,(H,28,29)/t11-,12-/m0/s1
Chemical Name
(12S)-8-[4-[(2S)-2-aminopropanoyl]oxypiperidin-1-yl]-7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
Synonyms
WCK2349 Alalevonadifloxacin WCK-2349 WCK 2349
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.3177 mL 11.5886 mL 23.1771 mL
5 mM 0.4635 mL 2.3177 mL 4.6354 mL
10 mM 0.2318 mL 1.1589 mL 2.3177 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration: mg/mL;

Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Contact Us